---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-036163"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:27:09.740922+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioLife Q2 revenue $28.3M (-3% YoY), net loss $7.1M; raises FY24 revenue guidance to $99-101M

## Summary
- Q2 total revenue $28.3M (-3% YoY, +6% seq); Cell Processing $18.0M (+11% seq).
- GAAP net loss from cont. ops $7.1M (incl $4.1M iVexSol write-off) vs $5.5M loss YoY; adj net loss $2.3M.
- GAAP gross margin 51% vs 35% YoY; non-GAAP adj gross margin 52% vs 45%.
- Adjusted EBITDA $4.8M (17% rev) vs $1.7M (6%) YoY.
- Raises FY2024 revenue guidance to $99-101M from $95.5-100M; Cell Processing to $70-71M.

## SEC filing metadata
- accession: 0001628280-24-036163
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828024036163/0001628280-24-036163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828024036163/blfs-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-036163
- JSON: https://secwatch.observer/filing/0001628280-24-036163.json
- Plain text: https://secwatch.observer/filing/0001628280-24-036163.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.